TITLE

Loss of Response and Requirement of Infliximab Dose Intensification in Crohn's Disease: A Review

AUTHOR(S)
Gisbert, Javier P.; Panés, Julián
PUB. DATE
March 2009
SOURCE
American Journal of Gastroenterology;Mar2009, Vol. 104 Issue 3, p760
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
OBJECTIVES:To review the frequency with which infliximabloses its effect and dose “intensification” is required for Crohn's disease treatment.METHODS:Bibliographical searches were performed in MEDLINE, and European (ECCO) and American (DDW) Congresses. Studies evaluating loss of efficacy and requirement of infliximab dose intensification—defined either as an increase of the infliximab dose (generally from 5 mg/kg to 10 mg/kg) or as a decrease in the frequency of infusion (to as often as every 4 weeks)—in Crohn's disease patients were included.RESULTS:Sixteen studies evaluating the incidence of loss of response to infliximab in Crohn's disease patients were found. A total of 2,236 patients were included (the majority of them receiving a three-dose induction regimen at weeks 0, 2, and 6, followed by maintenance therapy every 8 weeks), providing 6,284 patient-years of follow-up. The mean percentage of patients with loss of infliximab response was 37%. However, as the follow-up time varied markedly among studies, the risk of losing response to infliximab is better expressed as the incidence of this complication per patient-year of follow-up. Therefore, the annual risk for loss of infliximab response was calculated to be 13% per patient-year.CONCLUSIONS:A variable but relevant proportion of Crohn's disease patients on long-term infliximab treatment lose response. This may be interpreted in two different but compatible ways: a positive view, highlighting that infliximab therapy is relatively durable, with the majority of patients predicted to continue infliximab treatment at least during the first year; or a negative view, interpreting that a significant proportion of Crohn's disease patients—more than 10% per patient-year of infliximab treatment—on long term will lose response and will require an increase in dose and/or decrease in infusion interval.Am J Gastroenterol 2009; 104: 760–767; doi:10.1038/ajg.2008.88; published online 27 January 2009
ACCESSION #
36803376

 

Related Articles

  • Locking the Door to Leukocytes: Use of Integrin Inhibitors for the Treatment of Crohn's Disease. Dryden. Jr, Gerald W. // Clinical Medicine Insights: Therapeutics;2010, Issue 2, p897 

    Inflammatory Bowel Disease (IBD) treatments are rapidly evolving. Current knowledge of the immunopathology responsible for IBD grows on a daily basis. These scientific discoveries are quickly being translated into clinical advances for improved treatment of IBD patients. The breakthrough in...

  • Infliximab: A Review of its use in the Treatment of Pediatric Crohn's Disease. Broder, Arkady; Rosh, Joel R. // Clinical Medicine Insights: Therapeutics;2010, Issue 2, p235 

    The past decade has brought great change to the treatment of pediatric Crohn's disease. The majority of affected patients now receive therapy directed at the underlying immune dysregulation that is associated with this chronic disease. The monoclonal antibodies directed against tumor necrosis...

  • TNF blockers the future for Crohn's. Pownall, Mark // GP: General Practitioner;6/2/2006, p8 

    The article informs that clinical trial results suggest that Crohn's disease patients treated with TNF-alpha inhibitors can reach and maintain remission. Currently, Crohn's disease is treated with steroids which reduce inflammatory flares of the disease, but have no benefits in inducing...

  • INFLAMMATORY BOWEL DISEASE.  // Current Medical Literature: Gastroenterology;2004, Vol. 23 Issue 2, p47 

    Presents several abstracts of the articles related to gastroenterology. "A Randomised Placebo Controlled Trial of Pegylated Interferon Alpha in Active Ulcerative Colitis," by H. Tilg, H. Vogelsang, O. Ludwiczek, H. Lochs, A. Kaser, and J. F. Colombel; "The Safety Profile of Infliximab in...

  • Infliximab in inflammatory bowel disease: attention to adverse events. UYANIKOGLU, A.; ERMIS, F.; AKYUZ, F.; PINARBASI, B.; BARAN, B.; AYDOGAN, T.; DEMIR, K.; BESISIK, F.; KAYMAKOGLU, S. // European Review for Medical & Pharmacological Sciences;2014, Vol. 18 Issue 16, p2337 

    OBJECTIVE: TO assess the efficacy and adverse effects of infliximab in patients with Crohn's disease and ulcerative colitis who are resistant to conventional therapy or having fistulising type Crohn's disease. PATIENTS AND METHODS: The patients with a diagnosis of inflammatory bowel disease...

  • Adalimumab strides forward in Crohn's disease.  // PharmacoEconomics & Outcomes News;9/19/2009, Issue 587, p5 

    The article discusses research which compared the cost effectiveness of adalimumab and infliximab for treating severely active Crohn's disease. It references a study by A. P. Yu et al published in the July 2009 issue of the journal "PharmacoEconomincs." Results of the study showed that fewer...

  • Infliximab and newly diagnosed neoplasia in Crohn's disease: a multicentre matched pair study. Biancone, L.; Orlando, A.; Kohn, A.; Colombo, E.; Sostegni, R.; Angelucci, E.; Rizzello, F.; Castiglione, F.; Benazzato, I.; Papi, C.; Meucci, G.; Riegler, G.; Petruzziello, C.; Mocciaro, F.; Geremia, A.; Calabrese, E.; Cottone, M.; Pallone, F. // Gut;Feb2006, Vol. 55 Issue 2, p228 

    Background and aims: The widespread use of anti-tumour necrosis factor α antibody (Infliximab) in Crohn's disease (CD) raises concerns about a possible cancer risk in the long term. In a matched pair study, we assessed whether Infliximab is associated with an increased risk of neoplasia....

  • Azathioprine/infliximab/prednisolone.  // Reactions Weekly;6/30/2007, Issue 1158, p9 

    The article describes the case of a 57-year-old woman who developed pneumocystis carinii pneumonia during treatment with azathioprine, infliximab and prednisolone for Crohn's disease. Surgical findings showed perforation from a microabscess. The patient undergone resection of the perforation...

  • Predictors of infliximab failure after azathioprine withdrawal in Crohn's disease treated with combination therapy.  // Inflammatory Bowel Disease Monitor;2010, Vol. 11 Issue 2, p81 

    The article discusses a retrospective and observational study which investigates the role of the combined azathioprine and infliximab therapies in treating patients with luminal Crohn's disease in France. Around 79% of the patients are claimed under azathioprine treatment before the infliximab...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics